Dirk Thye
Chief Executive Officer at Quince Therapeutics Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Quince Therapeutics Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Quince Therapeutics Inc. June 5, 202499.4%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 10, 2025 | Quince Therapeutics Inc. | Gift | −739,885 | — | — |
| Dec 10, 2025 | Quince Therapeutics Inc. | Gift | +739,885 | — | — |
| Jun 18, 2025 | Quince Therapeutics Inc. | Grant or award | +150,944 | $1.20 | $181,133 |
| Aug 30, 2024 | Quince Therapeutics Inc. | Open-market purchase | +77,000 | $0.70 | $53,900 |
| Aug 29, 2024 | Quince Therapeutics Inc. | Open-market purchase | +77,500 | $0.69 | $53,475 |
| Jan 16, 2024 | Quince Therapeutics Inc. | Option exercise | +90,531 | $0.55 | $49,792 |
| Jan 16, 2024 | Quince Therapeutics Inc. | Option exercise | +149,999 | $0.94 | $140,999 |
| Aug 10, 2023 | Quince Therapeutics Inc. | Open-market purchase | +88,000 | $1.26 | $110,880 |
| Aug 8, 2023 | Quince Therapeutics Inc. | Open-market purchase | +80,000 | $1.24 | $99,200 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.